Journal of Antivirals & Antiretrovirals
Open Access
ISSN: 1948-5964
ISSN: 1948-5964
Department of Biotechnology, Center for Genetic Engineering and Biotechnology, Havana, Cuba
Research Article
Repurposing NASVAC, A Hepatitis B Therapeutic Vaccine, for Pre-and Post-exposure Prophylaxis of SARS-CoV-2 Infection
Author(s): Sheikh Mohammad Fazle Akbar*, Mamun Al Mahtab, Julio Cesar Aguilar, Md. Helal Uddin, Sakirul Islam Khan, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo and Yoichi Hiasa
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus 2019 (COVID-19)
have led to tens of millions of cases and millions of deaths around the world. Although more than a year has passed
since the emergence of COVID-19, more waves of the pandemic, with new variants of the deadly virus, have been
reported. It seems that the virus will continue to infect people for years or decades to come and thus lead to more
illnesses and deaths. The experiences last year regarding limiting the transmission of the virus indicate that one or
more traditional methods of containment may not be effective; further, even vaccination may not give adequate
immunity to society. On the other hand, eliminating the virus using drugs capable of eradicating SARS-CoV-2 from
infected host may not be an achievable goal. Based on these realities and after explo.. View More»
DOI:
10.35248/1948-5964.21.s20.004